NDAINTRA-ARTERIALSOLUTION
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ABLYSINOL (alcohol) by Gen Pharmaceuticals is intra-arterial catheter into a target septal vessel, which causes the hypertrophied septum to thin. First approved in 2018.
Drug data last refreshed 6h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ABLYSINOL (alcohol) is an intra-arterial solution approved in 2018 for the treatment of hypertrophic cardiomyopathy. It works by delivering alcohol via catheter into a target septal vessel, causing the hypertrophied septum to thin and improve cardiac function. This is a specialized interventional cardiology product with a narrow, well-defined patient population.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), suggesting stable commercial operations but limited expansion opportunities for sales and marketing teams.
Mechanism of Action
intra-arterial catheter into a target septal vessel, which causes the hypertrophied septum to thin.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Daridorexant for Alcohol Use Disorder
Started Jan 2027
150 enrolled
Alcohol Use Disorder
Alcohol Neurolysis and Capsaicin for Postamputation Pain (PAP)
Started Oct 2026
120 enrolled
Postamputation Pain
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
Started Sep 2026
274 enrolled
Liver Diseases, Alcoholic
Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients
Started Sep 2026
75 enrolled
Alcohol WithdrawalAlcohol AbstinenceAlcohol Use Disorder
Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use
Started Sep 2026
64 enrolled
Alcohol Use DisorderInflammatory ResponseCraving
Worked on ABLYSINOL at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.